Home
HelpTest Code 2DIS Human Leukocyte Antigens (HLA)-DR-DQ Disease Association Typing Low Resolution, Blood
Specimen Required
Container/Tube: Yellow top (ACD solution A or B)
Specimen Volume: 6 mL
Collection Instructions: Send whole blood in original tube. Do not aliquot.
Additional Information: Specimen acceptability is based on extracted DNA concentration and not sample age.
Useful For
Determining class II human leukocyte antigens (HLA) to identify potential disease associations or markers for drug hypersensitivity
Method Name
Polymerase Chain Reaction (PCR)/Next-Generation Sequencing (NGS)
Reporting Name
HLA-DR-DQ DisAssoc Typing LowRes,BSpecimen Type
Whole Blood ACDSpecimen Minimum Volume
3 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole Blood ACD | Ambient (preferred) | ||
| Refrigerated | |||
Reference Values
Not applicable
Interpretation
Interpretation depends on the rationale for ordering the test.
Clinical Reference
1. Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaki Y. Microdroplet testing for HLA-A, B, C and D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol. 1978;69(2):103-120
2. Colinas RJ, Bellisario R, Pass KA. Multiplexed genotyping of beta-globin variants form PCR-amplified newborn blood spot DNA by hybridization with allele-specific oligodeoxynucleotides coupled to an array of fluorescent microspheres. Clin Chem. 2000;46(7):996-998
3. Kennedy AE, Ozbek U, Dorak MT. What has GWAS done for HLA and disease associations? Int J Immunogenet. 2017;44(5):195-211. doi:10.1111/iji.12332
4. Caillat-Zucman S. New insights into the understanding of MHC associations with immune-mediated disorders. HLA. 2017;89(1):3-13. doi:10.1111/tan.12947
5. Howell WM. HLA and disease: guilt by association. Int J Immunogenet. 2014;41(1):1-12. doi:10.1111/iji.12088
6. Profaizer T, Pole A, Monds C, Delgado JC, Lazar-Molnar E. Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. Hum Immunol. 2020;81(7): 354-360
Day(s) Performed
Monday, Thursday
Report Available
7 to 17 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81375
81376 x3
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| 2DIS | HLA-DR-DQ DisAssoc Typing LowRes,B | 96640-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 2DA02 | DRDQ DisAssoc Comment | 96625-9 |
| 2DA03 | DRB1 - 1 Equivalent | 57298-2 |
| 2DA04 | DRB1 - 2 Equivalent | 57298-2 |
| 2DA05 | DRB1 - 1 Molecular | 96664-8 |
| 2DA06 | DRB1 - 2 Molecular | 96664-8 |
| 2DA07 | DRB345 - 1 Equivalent | 96673-9 |
| 2DA08 | DRB345 - 2 Equivalent | 96673-9 |
| 2DA09 | DRB345 - 1 Molecular | 96672-1 |
| 2DA10 | DRB345 - 2 Molecular | 96672-1 |
| 2DA11 | DQB1 - 1 Equivalent | 53938-7 |
| 2DA12 | DQB1 - 2 Equivalent | 53938-7 |
| 2DA13 | DQB1 - 1 Molecular | 78017-1 |
| 2DA14 | DQB1 - 2 Molecular | 78017-1 |
| 2DA15 | DQA1 - 1 Molecular | 96654-9 |
| 2DA16 | DQA1 - 2 Molecular | 96654-9 |
| 2DA17 | DPB1 - 1 Molecular | 96648-1 |
| 2DA18 | DPB1 - 2 Molecular | 96648-1 |
| 2DA19 | DPA1 - 1 Molecular | 96643-2 |
| 2DA20 | DPA1 - 2 Molecular | 96643-2 |
| LRTM2 | Test Method | 85069-3 |
Forms
If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.